Placebo + 375 mg CK-2017357 + 500 mg CK-2017357
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intermittent Claudication
Conditions
Intermittent Claudication, Peripheral Artery Disease
Trial Timeline
May 1, 2010 → Mar 1, 2011
NCT ID
NCT01131013About Placebo + 375 mg CK-2017357 + 500 mg CK-2017357
Placebo + 375 mg CK-2017357 + 500 mg CK-2017357 is a phase 2 stage product being developed by Cytokinetics for Intermittent Claudication. The current trial status is completed. This product is registered under clinical trial identifier NCT01131013. Target conditions include Intermittent Claudication, Peripheral Artery Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01131013 | Phase 2 | Completed |
Competing Products
12 competing products in Intermittent Claudication
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fluticasone propionate (Flovent Diskus) 250 mcg + budesonide 400 mcg | AstraZeneca | Approved | 85 |
| LLG783 + Placebo | Novartis | Phase 2 | 52 |
| Azithromycin plus chloroquine + sulfadoxine-pyrimethamine | Pfizer | Phase 3 | 76 |
| ataciguat (HMR1766) + placebo + cilostazol | Sanofi | Phase 2 | 51 |
| Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 + Ad2/HIF-1α/VP16 | Sanofi | Phase 2 | 51 |
| SL650472, Clopidogrel | Sanofi | Phase 2 | 51 |
| Givosiran | Alnylam Pharmaceuticals | Phase 1/2 | 38 |
| Givosiran + 5-probe cocktail | Alnylam Pharmaceuticals | Phase 1 | 30 |
| givosiran (ALN-AS1) + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Sapropterin Dihydrochloride | BioMarin Pharmaceutical | Phase 2 | 49 |
| Tetrahydrobiopterin 10 mg/kg + Tetrahydrobiopterin 20 mg/kg + L-Ascorbate + L-Arginine | BioMarin Pharmaceutical | Phase 1 | 30 |
| Pimavanserin 34 mg + Placebo | Acadia Pharmaceuticals | Phase 2 | 47 |